| Literature DB >> 16701144 |
Oliver Cromwell1, Helmut Fiebig, Roland Suck, Helga Kahlert, Andreas Nandy, Jens Kettner, Annemie Narkus.
Abstract
Recombinant DNA technology has delivered the prospect of a new generation of preparations for allergen-specific immunotherapy. The first clinical studies with recombinant allergens have yielded encouraging results, suggesting that there is a good chance that such preparations will become available for use in the routine management of allergic disease.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16701144 DOI： 10.1016/j.iac.2006.02.001
Source DB: PubMed Journal: Immunol Allergy Clin North Am ISSN： 0889-8561 Impact factor: 3.479